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 3 
Introduction 
Autism Spectrum Disorders (ASDs) are a spectrum of psychiatric 
conditions characterized by three major abnormal domains: limited or 
absent verbal and non verbal communication, a lack of reciprocal social 
communication or responsiveness, and repetitive, stereotyped and ritualistic 
patterns of interests and behaviors [1, 2]. The term “autism spectrum 
disorders” is used as shorthand to refer to any patient meeting these 
diagnostic criteria. But beyond this unifying definition, an extreme degree 
of clinical heterogeneity lies, ranging from profound to moderate 
impairments, always with functional disabilities. ASDs in fact include 
Autism itself (the prototypic pervasive developmental disorder, OMIM 
209850); Asperger syndrome (see ASPG1; OMIM 608638); the pervasive 
developmental disorder, not otherwise specified (PDD-NOS); and Rett 
Syndrome (OMIM 312750). So, autism is not a single disease, rather a 
complex phenotype thought to be caused by different types of defects in 
common pathways, producing similar behavioral phenotypes. ASDs are 
usually diagnosed within three years, and have a prevalence of about 1/100, 
but closer to 1/300 for typical autism [3]. ASDs are more common in male 
than female patients, with a 4:1 ratio [4, 5]. Twin and family studies have 
conclusively established the strong genetic contribution to ASDs, with 
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concordance rates of 82–92% in monozygotic twins versus 1–10% in 
dizygotic twins. 
Intellectual disabilities coexist in approximately two-thirds of individuals 
with ASDs, except for Asperger syndrome, in which mental retardation is 
conspicuously absent [6]. 
In approximately 10–25% of the affected individuals, autism is 
„syndromic‟, occurring in children with a known genetic (such as fragile X 
syndrome, tuberous sclerosis, neurofibromatosis) or environmental 
(valproic syndrome, or brain herpes simplex infection) disorder [4, 
6].Similarly to other child psychiatric disorders, two opposite hypotheses 
have been proposed to elucidate the genetics of ASDs. The early inability 
to detect mutations in single genes, that could explain ASDs as Mendelian 
inheritance diseases, prompted some geneticists to consider autism as a 
polygenic trait, and led to the ascendance of the “common variant common 
disease” hypothesis. This model supposes that any given common allele 
(defined as 5% or greater population frequency) is likely to be neither 
necessary nor sufficient to lead to the clinical phenotype, but in 
combination with other risk alleles would contribute to the emergence of 
the disease. Therefore, model-free linkage studies, such as affected sib-pair 
analyses, were performed to identify susceptibility genes. Although many 
genomic regions were detected, only a restricted number of loci were 
replicated in independent scans (e.g. 7q31 and 17q11); probably, an 
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explanation for the lack of definitive results is the much greater than 
anticipated degree of locus heterogeneity in ASDs. Afterward, the 
technological feasibility of genotyping one or a small number of common 
alleles in large cohorts of patients led to the publication of several studies, 
presenting interesting findings. These included the identification of EN2 
[7], the oncogene MET [8], and CNTNAP2 [9] as autism-susceptibility 
genes. Finally, genome wide association studies (GWAS) with high-density 
Single Nucleotide Polymorphism (SNP) arrays, emerged as the gold 
standard for the identification of common small-effect alleles, have been 
applied to autism. Association studies provide major advantages compared 
with linkage studies: first, studies can include large samples of subjects 
because they are not restricted to multiplex families with two or more 
affected children. Second, the genomic regions associated with the trait are 
much narrower than in linkage studies, because linkage disequilibrium 
between relatively close genomic regions is less likely to affect the 
association. In addition, SNP arrays can be used to detect structural variants 
such as Copy Number Variants (CNVs), which may also contribute to the 
development of the disease [10], as we‟ll discuss later. Unfortunately, the 
three largest GWAS, performed on more than 1000 patients in each study, 
failed to detect the same genes [11-13]. The first one identified a significant 
association of ASDs to an intragenic region (5p14.1) between Cadherin 9 
and Cadherin 10 genes. The second study found an association to a SNP 
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near Semaphorin 5A, and the third evidenced an association to the 
MACROD2 gene. 
Despite the GWAS has failed to identify a significant proportion of the 
genetic risk for autism, the polygenic model cannot be excluded for several 
reasons. First, it is now well established that the clinical outcome of most 
“classical” monogenic disorders is actually modulated by additional genetic 
variations. Second, the experience in other polygenic traits, blood pressure 
and height for example, has shown that the effect of a single common 
variant on the phenotype can be very low (odds ratio <2) and can require a 
large sample size (>15 000 subjects) in order to be detected [14]; so far, the 
current GWAS scans in ASDs – the largest were performed on cohorts of 
less than 2000 subjects – may have missed the necessary statistical power 
to detect such common alleles with low effect. Finally, the polygenic 
heredity of autism could be explained by the presence of both common and 
rare variants: the number of deleterious mutations within the genome of 
one individual remains difficult to establish, but it is likely that a 
combination of multiple common and rare variants (such as small CNVs or 
coding and regulatory variations, not detect by GWAS) could affect 
specific biological pathways and therefore increase the risk for developing 
autism. 
So, the converging results of both GWAS and linkage studies that have 
discovered only a small proportion of the genetic risk for common 
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disorders [14], the increasing relevance of rare variant findings in other 
neuropsychiatric area, the likely pathogenic involvement of CNVs and the 
identification of apparently monogenic forms of autism, each time affecting 
a limited number of patients (1–2% for the most replicated genes), have led 
some Authors to opt for the hypothesis of “rare variant common disease” 
(RVCD) to explain the etiology of ASDs. By this model, the “autisms” are 
a very heterogeneous group of neuropsychiatric phenotypes caused by rare 
variations (e.g., point mutations or CNVs) in different genes involved in 
common pathways (in this model, a single highly penetrant mutation would 
be sufficient to produce autism). 
In recent years, enormous progress has been achieved in detecting genomic 
structural variants (i.e., CNVs) more or less rare [15], and at least nine 
studies have searched for such genomic imbalances in patients with ASDs 
[16-24]. Unfortunately, differences in the criteria used for patients‟ 
selection, genotyping methodologies and algorithms applied to detect 
deletions and duplications make the comparison of these results difficult. 
Nevertheless, it seems that there is a significant increase in rare inherited 
and de novo CNVs in the ASDs population compared with the general 
population. The overall rate of de novo CNVs in ASDs could range from 
5–10% compared with 1% in the general population [20]. Not surprisingly, 
the frequency of rare and de novo CNVs increases for families with only 
one affected child (7–10%) compared with families with two or more 
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affected children (2–3%) [20]. The presence of dysmorphic features in the 
patient also increases the odds of detecting a rare or de novo CNV in up to 
27.5% [17]. Based on current findings, the majority of the CNVs 
apparently affect only one copy of the gene (which can be either deleted or 
duplicated), suggesting that abnormal gene dosage or expression might 
play a key role in susceptibility to ASDs [25]. 
To date, despite the large efforts spent to identify common and rare alleles, 
the number of genes definitively accepted as high risk factors remains quite 
small. Nevertheless, lists of candidate genes are proliferating exponentially: 
for example, a list of 219 genes is available at AutDB, a public, web-based 
database for autism research (http://www.mindspec.org/autdb.html). 
Obviously, most of these genes remain only “candidates” because their 
association to autism was not confirmed by replication and/or validated by 
functional studies. 
These candidate genes generally participate to three major biological 
processes, all related to the development and functioning of neuronal 
circuits.  
(a) At the synapse, the following proteins have been associated to 
ASDs: adhesion molecules (cadherins, protocadherins, neuroligins 
and neurexins) involved in presynaptic assembly; scaffold proteins 
(SHANK and DLGAP2), which provide a link between 
postsynaptic membrane proteins and actin; receptors for glutamate 
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(GLUR) and GABA (GABAR), which play a major role in 
excitatory and inhibitory currents, respectively; FMRP, which 
regulates local translation of synaptic proteins, together with PTEN, 
NF1, TSC1 and TSC2, and c-MET; UBE3A, which participates in 
the targeting of proteins to the proteasome. 
(b) In the neuron nucleus, the Methyl-CpG binding protein 2 and 
transcription factors like MEF2C regulate the expression of genes 
involved in neuronal circuit. 
(c) At the node of Ranvier, contactins and CNTNAP2 organize the 
junction between the outgrowing axon and glia, together with cell 
adhesion and secreted proteins as NRCAM and SEMA5A. 
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Aim of the thesis 
The aim of this study is to detect, through high-resolution array-CGH 
analysis, unreported Copy Number Variants in a cohort of 120 Italian 
autistic patients. After a validation of such results, through an in silico 
analysis of these variants, we expect to generate a list of new candidate 
genes in autism, which may be further investigated to better delineate their 
actual role in the etiology of ASDs. 
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Patients and methods 
After obtaining informed written consent from parents or legal guardians, 
we collected blood samples from 120 ASD children (94 males, 26 female 
s). Individuals were included in this research project only if the following 
criteria were fulfilled: 
 matching DSM-IV-TR criteria for PDD/ASD and scoring cut-off in 
Autism Diagnostic Interview-Revised [26] and/or in Autism 
Diagnostic Observation Schedule-Generic [27]; 
 being at least 3 years of age at the time of entering the research 
project.  
The exclusion criteria were as follows: 
 presence of profound mental retardation; 
 history of serious head injury, encephalitis or tumors; 
 presence of metabolic disease or known genetic syndrome. 
All patients had a normal G-band karyotype, and were FRAXA (mutations 
or expansions) negative; subtelomeric rearrangements were also excluded. 
DNA extractions were performed by salting out procedures. DNA quantity 
and quality were tested through NANODROP ND1000 spectrophotometer 
(Euroclone). 
Autistic subjects were screened by array-CGH with the Agilent 60K, 180K 
and 244K arrays (median resolution 41.5 kb, 13 kb and 8.9 kb 
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respectively). Our array platforms were calibrated through a series of self-
self and sex-mismatched hybridizations to experimentally establish the 
false positive and the false negative rates and the threshold to define copy 
number changes. A series of experiments using reference samples with 
DNA imbalances of variable but well-known sizes allowed us to check for 
the reliability and for the real resolution of our platform. 
In addition, one male and one female (Coriell NA10851/ NA15510) DNAs, 
whose genomic CNV content has been well characterized by several 
studies, were used as male and female references, respectively. This 
strategy allowed us to discern between CNVs of reference DNA and those 
of sample DNA. Moreover, we were able to detect false negative results 
due to the presence of the same CNVs both in reference and sample. 
In principle, 500 ng of patient and reference DNAs were double-digested 
with 5 units each of RsaI and AluI (Promega) for two hours at 37°C. Each 
digested sample was labeled by random priming (Agilent Genomic DNA 
Labeling Kit PLUS) for two hours at 37°C, using Cy5−dUTP for the 
patient DNA and Cy3−dUTP for the reference DNA. Labeled products 
were combined and column purified with a Microcon YM-30 filter 
(Millipore). After denaturation and pre-annealing with 50 µg of Cot-1 
DNA (Invitrogen), DNAs were hybridized on a microarray at 65 °C with 
rotation for 40 hours. After two washing steps, the arrays were scanned on 
Agilent scanner and microarray images were analysed with Feature 
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Extraction software. Graphical representation of the results was obtained 
using the CGH-Analytics software. 
The Agilent software pipeline has been developed together with a series of 
Quality Control (QC) parameters that give an important support to estimate 
if an experiment is sufficiently well-performed or need to be repeated. For 
each array analyzed the Feature Extraction software creates a file reporting 
information related to the ratio intensities, background intensities, spots 
distribution, out-/in-liers distributions and relative intensities and all the 
parameters relevant to the data analysis. Intra-experiment statistical 
features present in the software pipeline include: number and spatial 
distribution of outliers, net signal statistics, local background inliers, 
foreground surface fit, plot of background-corrected signals, spatial 
distribution of Up and Down regulated features and plot of LogRatio versus 
average Log Signals. Inter-experiment statistical features include: 
reproducibility statistics, microarray uniformity, reproducibility plot (spike-
ins), spike-in LogRatio statistics and LogRatio plot for spike-ins.  
The CNVs reported in our patients were compared with those reported in 
the most important database of genomic variants identified in normal 
controls, the “Toronto database” (http://projects.tcag.ca/variation/), and a 
database created in our laboratory 
(http://dbcnv.oasi.en.it/gvarianti/index.php), which collects CNVs data 
from the most important Italian Institutions studying MR and autistic 
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patients through array CGH platforms. Array-CGH findings of particular 
interest (i.e. non-polymorphic CNVs) were confirmed by alternative 
techniques, such as Multiplex Ligation-dependent Probe Amplification 
(MLPA) or Fluorescent In Situ Hybridization (FISH) assays, and tested on 
parents when possible. 
We also referred to three international databases which collect information 
on genes and CNVs associated to autism 
(http://www.mindspec.org/autdb.html; http://wren.bcf.ku.edu/; 
http://projects.tcag.ca/autism_500k/). For the in silico study of the genes 
included in the reported CNVs, we referred to PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed), OMIM 
(http://www.ncbi.nlm.nih.gov/omim/) and Entrez Gene 
(http://www.ncbi.nlm.nih.gov/gene/) databases. 
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Results and Discussion 
Using the above mentioned Agilent protocol, 120 autistic patients were 
screened through high-resolution array-CGH assays. Compared to the 
reference DNA, each of them showed at least one CNV, but depending on 
the resolution of the array - which increased during the course of the 
project, as new array platforms were becoming available - this number 
could increase to ten and more. So, hundreds of CNVs were revealed and 
were to be interpreted. In order to assess the potential pathogenic role of 
these genomic imbalances, we defined an analytical procedure, consisting 
of several criteria that allowed us to prioritize polymorphic, “pathological” 
(P), “novel” (N) and “candidate” (C) CNVs and genes. The flowchart of 
this procedure is summarized in figure 1, and described in detail below. 
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Figure 1. Procedure used to select the candidate CNVs. In roman numerals, the three 
selection steps are represented. P = pathological, N = novel (non polymorphic), C = 
candidate. 
III in silico analysis: 
• size; 
• genes (REs, microRNAs) involved in cerebral development, in 
synapses, and so on  
• OMIM genes associated to neurodevelopmental conditions; 
• genes  belonging to gene families already involved in Autism 
I Elimination of polymorphic CNVs 
57 CNVs in 50 patients 
MLPA or FISH, parents 
II DB or  literature on Autism 
P>> 19/57 N>> 38/57 
C>> 18/38 
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Criteria used to assess a pathogenic role of CNVs and their overlapping 
genes 
The CNVs identified in the study were considered identical (recurrent) only 
if they were represented by the same probes and were of the same sign 
(loss or gain). As a first step, we searched for all the variants observed in 
the study within the Database of Genomic Variants, to eliminate from 
further investigations all the polymorphic variants: in so doing, we were 
able to select 57 different and non-polymorphic CNVs in 50 patients. 12 
patients showed 2 variations each, 4 CNVs were recurrent in two patients 
each, one CNV presented identical in size, but in loss in one patient, and in 
gain in another one. The size of these variants was very variable, ranging 
from 11 kilobases to 3.5 megabases; 32 were deletions, 26 were 
duplications. These CNVs were confirmed by alternative methods, i.e. 
MLPA or FISH assays, to exclude false positives, and were also 
investigated in the parents (when possible), to establish if they were 
inherited or de novo events. 
At this point, it was necessary to determine how to interpret these findings, 
and first understand which were to be considered pathogenic. So, the 
second selection step was the “replication”: each of the 57 non-
polymorphic CNVs was verified in the Autism and in the Italian databases 
described in the Methods, and in Pubmed, to search for the most recent data 
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literature; we considered a CNV pathological if it was already reported in 
autistic patients or (in one case, see below) if it contained one or more 
genes found mutated in autism. This analytical procedure enabled us to 
distinguish two groups of CNVs: 19 pathological, and 38 “novel” CNVs, 
never before associated to autism. 
The data resulting from the application of this criterion and the related 
information are reported in Table 1, part one. 
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patient gender 
CNV 
type 
heredity loss/gain chr cytoband 
size in 
Kb 
genes 
present in 
Autism DB 
or 
literature 
evidence 
03199 F P de novo DEL 1 q42.2 18 DISC1 YES inherited CNV  
02951 M P F DUP 2 p16.3 440 NRXN1 YES 
mutations and 
CNV 
03001 F P de novo DEL 2 p25.2 1 Mb SOX11 YES de novo CNV 
02875 M P F DUP 3 p26.3 500 
CNTN4 
CNTN6 
CNTN4 
YES 
CNTN6 NO 
CNV 
02919 M P de novo DEL 6 p21.32 128 SYNGAP1 YES 
mutations and 
CNV 
02331 M P ND DEL 6 q26 115 PARK2 YES CNV 
02433 M P ND DEL 7 q11.23 390 AUTS2 YES 
mutations and 
CNV 
03957 F P ND DEL 7 q31 61 DOCK4 YES CNV and SNP 
03841 M P F DEL 7 q35 35 CNTNAP2 YES 
CNV and rare 
variants 
03256 M P de novo DEL 9 p24.3-24.2 3.5 Mb DOCK8 YES de novo CNV 
03436 F P ND DEL 15 q11.2 425 NIPA1 YES CNV 
03476 M P F DEL 15 q11.2 443 NIPA1 YES CNV 
02104 M P de novo DEL 22 q11.2 139 PRODH YES CNV 
02985 F P de novo DEL 22 q11.2 139 PRODH YES CNV 
03788 M P M DEL 22 q11.21 116 
DGCR6 
PRODH 
YES CNV 
01579 M P M DUP 22 q11.2-q11 2.5 Mb 
PRODH 
TBX1 
YES CNV 
01875 F P de novo DEL 22 q13.33 25 SHANK3 YES 
CNV and 
mutations 
03233 F P de novo DUP X p22.2 2.7 Mb GRPR YES mutations 
02997 M P F DUP X p22.33 18 ASMT YES 
inherited 
CNVs, SNP, 
mutations 
02051 M P M DUP X p22.33 15 ASMT YES 
inherited 
CNVs, SNP, 
mutations 
03820 M P ND DUP X p22.33 15 ASMT YES 
inherited 
CNVs, SNP, 
mutations 
Table 1 (part one). CNV type P= pathological; heredity F= from father, M= from 
mother, ND= not determined; in bold the patients with two novel CNVs reported; 
coloured lanes represent the recurrent findings.  
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Of these 19 CNVs, reported in 21 patients (two pairs of patients had a 
recurrent CNV each), 13 were deletions, 6 were duplications. However, it 
should be noted that some duplications, having their breakpoints within a 
gene, may disrupt its normal genomic structure, so one can expect a 
haploinsufficiency of that gene, rather than an overexpression. 
8/21 patients had a de novo CNV, 8 subjects inherited their variant from an 
apparently healthy parent, and for 5 of them was not possible to investigate 
the parents. 
Interestingly, 4 patients (02331, 03436, 03788, and 03820) had one P and 
one C CNVs each, one patient (02997) had one P and one N CNVs. 
Two noteworthy findings:  
(i) the gastrin-releasing peptide receptor has been found disrupted in 
an autistic girl due to a X:8 translocation [28], and then mutated 
in other patients, but never before it has been found involved in a 
CNV. It is an intriguing finding that our patient # 03233 (also a 
female) has a totally duplicated GRPR gene (see Table 1, part 
one) suggesting that both increased and decreased dosage of 
GRPR could be pathogenic in autistic females;  
(ii) CNTNAP2 (contactin associated protein-like 2) is a well 
established and strong autism gene [29]. We found a patient (# 
03841 in Table 1, part one) bearing a deletion, inherited from the 
healthy father, encompassing only three probes, which lies 
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immediately proximal to the CNTNAP2 gene (see figure 2): we 
suspect that regulatory sequences of this gene were lost with the 
deletion. Our findings on these two autism genes are 
unprecedented and deserve further investigation to elucidate the 
precise molecular mechanism altering their function. 
 
Figure 2. A 35 Kb deletion in 7q35 proximal to the CNTNAP2 mRNA (grey bar). 
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Criteria used to assess a candidate role of CNVs and their overlapping 
genes 
38 CNVs were not previously described as polymorphic variants, and were 
never associated to autism. For the purpose of our study, they represented 
just the most intriguing findings, because these were the ones that could 
contain new genes of autism. To establish a priority order by which to 
submit these CNVs to further investigations, we applied the following 
criteria: 
 CNV size: large deletions and duplications were tentatively 
considered as candidate pathogenic; 
 positive in silico analyses: we performed on the gene content of the 
38 CNVs an in silico study, using the databases described in 
methods, and we considered candidate a CNV if it contained genes 
expressed in the central nervous system and involved in brain 
development, neuronal functioning, or synaptic plasticity; moreover, 
OMIM genes, already associated to other neurological and/or 
neuropsychiatric conditions, especially those ones involving 
disturbances of neurodevelopment (pathological and candidate); 
finally, genes belonging to families whose other members have 
already been associated to autism. In silico analysis was also carried 
out to detect potential regulatory elements, microRNAs and 
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evolutionary conserved elements related to brain development and 
function. To this aim, we mainly used databases providing 
information on the expression pattern, on the sequence and 
functional similarities with other organisms, and on the existence of 
mouse knockout models. Reference databases are listed in the 
Methods‟ section.  
De novo vs. inherited variant was not considered a selection criterion: in 
fact, though the de novo CNVs may represent highly penetrant candidate 
variations, the distinction between de novo and inherited CNVs was not 
taken into account. This choice was made to conform to the unified genetic 
theory for sporadic and inherited autism [30]. Indeed, according to this 
theory, causative CNVs may be inherited from an unaffected parent as well 
as de novo events. 
Thanks to these criteria, we selected 18 CNVs as “candidate” for further 
investigations. The second part of Table 1 shows these CNVs, and their 
candidate genes. The patients listed in table are 20, having been two CNVs 
reported twice each. 
Interestingly, 4 patients (03264, 01397, 01950, and 03799) had one C and 
one N CNVs each.  
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patient gender heredity loss/gain chr cytoband 
size in 
Kb 
genes 
Evidence for 
candidate 
02806 M F DEL 1 q21.1 3.1 Mb many size 
01995 F F DEL 2 q13 1.7 Mb many size 
072 M ND DUP 17 q12 408 many size 
02031 M F DUP 13 
p21.1-
21.2 
1.8 Mb 
many, 
PCDH17 
Size and GF 
01397 M de novo DEL 15 
q24.1-
24.2 
2.5 Mb 
many, 
SEMA7A 
Size and GF 
02331 M ND DUP 2 p12 325 CTNNA2 GF 
03264 M ND DEL 11 q22.3 223 GRIA4 GF 
03820 M ND DUP 4 q35.1 300 SLC25A4 GF 
03436 F ND DUP 5 q35.3 56 GRM6 GF 
02993 M M DUP 10 q22.1 309 
UNC5B 
SLC29A3 
CDH23 
GF 
02993S F M DUP 10 q22.1 309 
UNC5B 
SLC29A3 
CDH23 
GF 
03123 M M DEL 16 p12.1 79 HS3ST4 GF 
01950 M ND DUP X p22.33 11 ASMTL GF 
0176 M ND DEL X q28 52 TMEM185A GF 
03799 M ND DUP X q28 52 TMEM185A GF 
02571 M ND DEL 7 p12.1 96 COBL 
Neuronal 
morphogenesis 
02572 M ND DEL 7 p12.1 113 COBL 
Neuronal 
morphogenesis 
02627 M ND DUP 6 q22.33 63 ARHGAP18 Schizophrenia 
03153 F F DEL 7 q11.22 28 CALN1 Brain specific  
03788 M M DEL 15 q21.3 97 NEDD4 N 
 
Table 1 (part two). Heredity F= from father, M= from mother, ND= not determined; in 
bold the patients with two novel CNVs reported; coloured lanes represent the recurrent 
findings; 02993 and 02993S (in orange) are brother and sister; GF = gene belonging to 
Gene Families already associated to autism. 
 
 25 
As one can see at the top of the table, five variants, containing many genes, 
were considered candidates because of their significant size. In particular, 
patients 02806 and 01995 both inherited the CNV from the father, and need 
further considerations. Two other patients, 02031 and 01397, had two 
CNVs that were considered “candidates” for both their size and because 
they contained respectively protocadherin 17 and semaphorin 7A, two 
genes belonging to gene families already involved in autism. 
Eight other CNVs containing autism gene family members are listed in the 
middle of the table. The involved genes are: 
 CTNNA2 (catenin alpha 2), entirely duplicated in patient 02331; 
 GRIA4 (glutamate receptor, ionotrophic, AMPA 4), entirely deleted 
in patient 03264; 
 the solute carrier SLC25A4, entirely duplicated in patient 03820; 
 GRM6 (glutamate receptor, metabotropic 6), entirely duplicated in 
patient 03436; 
 SLC29A3 and cadherin 23 (see figure 3); 
 HS3ST4 (heparan sulfate glucosamine 3-O-sulfotransferase 4), 
interrupted by a small deletion in patient 03123; 
 ASMTL (acetylserotonin O-methyltransferase-like), an X linked gene 
interrupted by a very small duplication in the male patient 01950; 
 26 
 TMEM185A, a transmembrane protein found interrupted in two 
identical CNVs (one deletion and one duplication) in two male 
patients, 0176 and 03799. 
 
Figure 3. A 309 kb duplication in 10q22.1 in two patients, brother and sister, disrupting 
two genes (UNC5B and CDH23) and including the solute carrier SLC29A3. 
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Finally, a pathological effect due to an aberrant dosage could be supposed 
for the following genes, involved in microimbalances in the patients listed 
at the bottom of the table: COBL, ARHGAP18, CALN1, and NEDD4.  
COBL gene was found deleted in two unrelated male patients (figure 4); it 
encodes for the Cordon-blue protein, a multifunctional brain-enriched 
vertebrate protein that uses three C-terminal WH2 domains to associate 
with actin and regulate actin dynamics [31]. To the best of my knowledge, 
literature lacks of COBL knock out model, and the protein was never 
associated to a disease. 
 
Figure 4. A recurrent deletion in 7p12.1 including the COBL gene. 
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ARHGAP18 (figure 5), totally duplicated in one patient, belongs to a 
family of Rho GTPase-activating proteins that modulate cell signalling [32] 
and was very recently associated to schizophrenia [33]. 
 
Figure 5. A 63 kb duplication in 6q22.33 including the ARHGAP18 gene. 
 
Calneuron 1 (CALN1) gene is a brain specific member of the calmodulin 
superfamily [34] and never than before was linked to a neurodevelopmental 
disease. In one of our patients, it is interrupted by a 28 Kb deletion. 
Finally, NEDD4 is a very interesting dosage-sensitive regulatory protein of 
the brain (OMIM 602278) which was interrupted by a microdeletion in one 
patient. 
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Future studies 
To better delineate the possible role of the previously unreported CNVs in 
autism, we propose three parallel approaches, to be applied to the candidate 
variations described in the previous session. 
First of all, to investigate if these CNVs represent rare polymorphisms not 
yet described, rather than autism susceptibility factors, we have planned to 
screening for these CNVs both a control group of about 1000 Caucasian 
healthy individuals, and a greater cohort of autistic patients, by a targeted 
MLPA approach. This will allow us to filter out all CNVs with frequencies 
not statistically different among patients and controls. Therefore, all CNVs 
with frequencies significantly different between the two cohorts will be 
regarded as potentially causative of ASDs.  
Second, we propose to screen the array-CGH negative patients for a 
molecular analysis of the genes involved in the candidate variants: finding 
mutations in one of these genes could strongly confirm their pathological 
connotation. 
Third, for those imbalanced genes that we know to be expressed in blood, 
we propose a gene expression analysis, to verify their non-physiological 
expression and its functional significance. 
 30 
Acknowledgements 
This work was supported by Telethon grant (GGP08226). We‟d like to 
thank all the patients and their parents for participating in this study. The 
laboratory activities concerning this PhD thesis have been performed at the 
“Oasi Maria SS” Institute in Troina (Enna, Italy), in which the 
collaborating units were: 
 Laboratorio di Diagnosi Genetica, and especially dr. Daniela Di 
Benedetto; 
 Laboratorio di Genetica Molecolare (dr. Franco Calì, dr. Valeria 
Chiavetta, dr. Mirella Vinci); 
 U.O. di Neurologia e Neurofisiopatologia Clinica e Strumentale (dr. 
Maurizio Elia);  
 U.O. di Pediatria e Genetica Medica (dr. Corrado Romano); 
 U.O. di Neurologia per il Ritardo Mentale (dr. Sebastiano 
Musumeci, dr. Stefania Giusto); 
 U.O. di Psicologia (dr. Marinella Zingale, dr. Grazia Trubia). 
 31 
References 
1. Bailey A, Phillips W, Rutter M (1996) Autism: towards an integration of 
clinical, genetic, neuropsychological, and neurobiological perspectives. J 
Child Psychol Psychiat 37: 89-126. 
2. Risch N, Spiker D, Lotspeich L, Nouri N, Hinds D, et al (1999) A 
genomic screen of autism: evidence for a multilocus etiology. Am J Hum 
Genet 65: 493-507. 
3. Fernell E, Gillberg C (2010) Autism spectrum disorder diagnoses in 
Stockholm preschoolers. Res Dev Disabil 31: 680–685.  
4. Freitag CM (2007) The genetics of autistic disorders and its clinical 
relevance: a review of the literature. Mol Psychiatry 12: 2–22. 
5. Abrahams BS, Geschwind DH (2008) Advances in autism genetics: on 
the threshold of a new neurobiology. Nat Rev Genet 9: 341–355.  
6. Gillberg C, Coleman M (2000) The Biology of the Autistic Syndromes, 
Oxford University Press.  
7. Benayed R, Gharani N, Rossman I, Mancuso V, Lazar G (2005) Support 
for the homeobox transcription factor gene ENGRAILED 2 as an autism 
spectrum disorder susceptibility locus. Am J Hum Genet 77(5):851-68. 
8. Campbell DB, Sutcliffe JS, Ebert PJ, Militerni R, Bravaccio C (2006) A 
genetic variant that disrupts MET transcription is associated with autism. 
Proc Natl Acad Sci U S A 103(45):16834-9. 
 32 
9. Alarcón M, Abrahams BS, Stone JL, Duvall JA, Perederiy JV (2008) 
Linkage, association, and gene-expression analyses identify CNTNAP2 as 
an autism-susceptibility gene. Am J Hum Genet 82(1):150-9. 
10. Cook EH Jr, Scherer SW (2008) Copy-number variations associated 
with neuropsychiatric conditions. Nature 455: 919–923.  
11. Wang K, Zhang H, Ma D, Bucan M, Glessner JT, et al (2009) Common 
genetic variants on 5p14.1 associate with autism spectrum disorders. 
Nature 459: 528–533.  
12. Weiss LA, Arking DE, Gene Discovery Project of Johns Hopkins & the 
Autism Consortium, Daly MJ, Chakravarti A, et al (2009) A genome-wide 
linkage and association scan reveals novel loci for autism. Nature 461: 
802–808.  
13. Anney, R. et al. (2010) A genomewide scan for common risk variants 
nominates phospholipase D and polysialyltransferase proteins for a role in 
autism (Submitted). 
14. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, et al 
(2009) Finding the missing heritability of complex diseases. Nature 
461(7265): 747-753. 
15. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, et al (2010) 
Origins and functional impact of copy number variation in the human 
genome. Nature 464(7289): 704-12.  
 33 
16. Autism Genome Project Consortium, Szatmari P, Paterson AD, 
Zwaigenbaum L, Roberts W et al (2007) Mapping autism risk loci using 
genetic linkage and chromosomal rearrangements. Nat Genet 39(3): 319-
28. 
17. Jacquemont ML, Sanlaville D, Redon R, Raoul O, Cormier-Daire V, et 
al (2006) Array-based comparative genomic hybridisation identifies high 
frequency of cryptic chromosomal rearrangements in patients with 
syndromic autism spectrum disorders. J Med Genet 43(11): 843-9.  
18. Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, et al (2009) 
Autism genome-wide copy number variation reveals ubiquitin and neuronal 
genes. Nature 459(7246): 569-73. 
19. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L et al (2008) 
Structural variation of chromosomes in autism spectrum disorder. Am J 
Hum Genet 82(2): 477-88. 
20. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, et al (2007) 
Strong association of de novo copy number mutations with autism. Science 
316(5823): 445-9. 
21. Cho SC, Yim SH, Yoo HK, Kim MY, Jung GY, et al (2009) Copy 
number variations associated with idiopathic autism identified by whole-
genome microarray-based comparative genomic hybridization. Psychiatr 
Genet 19(4): 177-85. 
 34 
22. Christian SL, Brune CW, Sudi J, Kumar RA, Liu S, et al (2008) Novel 
submicroscopic chromosomal abnormalities detected in autism spectrum 
disorder. Biol Psychiatry 63(12): 20. Bucan M, Abrahams BS, Wang K, 
Glessner JT, Herman EI, et al (2009) Genome-wide analyses of exonic 
copy number variants in a family-based study point to novel autism 
susceptibility genes. PLoS Genet 5(6):e1000536. 
23. Bucan M, Abrahams BS, Wang K, Glessner JT, Herman EI, et al 
(2009) Genome-wide analyses of exonic copy number variants in a family-
based study point to novel autism susceptibility genes. PLoS Genet 2009 
5(6):e1000536.  
24. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, et al (2010) 
Functional impact of global rare copy number variation in autism spectrum 
disorders. Nature 466(7304): 368-72. 
25. Toro R, Konyukh M, Delorme R, Leblond C, Chaste P, at al (2010) 
Key role for gene dosage and synaptic homeostasis in autism spectrum 
disorders. Trends Genet 26(8): 363-72. 
26. Lord C, Rutter M, Le Couteur A (1994) Autism Diagnostic Interview-
Revised: a revised version of a diagnostic interview for caregivers of 
individuals with possible pervasive developmental disorders. J Autism Dev 
Disord 24: 659-685. 
27. Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, et al (2000) 
The autism diagnostic observation schedule-generic: a standard measure of 
 35 
social and communication deficits associated with the spectrum of autism. J 
Autism Dev Disord 30: 205-223. 
28. Ishikawa-Brush Y, Powell JF, Bolton P, Miller AP, Francis F, et al 
(1997) Autism and multiple exostoses associated with an X;8 translocation 
occurring within the GRPR gene and 3' to the SDC2 gene. Hum Mol Genet 
6(8): 1241-50. 
29. Bakkaloglu B, O'Roak BJ, Louvi A, Gupta AR, Abelson JF, et al 
(2008) Molecular cytogenetic analysis and resequencing of contactin 
associated protein-like 2 in autism spectrum disorders. Am J Hum Genet 
82(1): 165-73. 
30. Zhao X, Leotta A, Kustanovich V, Lajonchere C, Geschwind DH, et al 
(2007) A unified genetic theory for sporadic and inherited autism. Proc 
Natl Acad Sci U S A 104(31):12831-6. 
31. Renault L, Bugyi B, Carlier MF (2008) Spire and Cordon-bleu: 
multifunctional regulators of actin dynamics. Trends Cell Biol 18(10): 494-
504. 
32. Potkin SG, Macciardi F, Guffanti G, Fallon JH, Wang Q, et al (2010) 
Identifying gene regulatory networks in schizophrenia. Neuroimage 53(3): 
839-47. 
33. Potkin SG, Turner JA, Fallon JA, Lakatos A, Keator DB, et al (2009) 
Gene discovery through imaging genetics: identification of two novel genes 
associated with schizophrenia. Mol Psychiatry 14(4): 416-28. 
 36 
34. Wu YQ, Lin X, Liu CM, Jamrich M, Shaffer LG (2001) Identification 
of a human brain-specific gene, calneuron 1, a new member of the 
calmodulin superfamily. Mol Genet Metab 72(4): 343-50. 
